Fan Yaohua, Zhu Xiyan, Lan Qiuping, Lou Fang, Zheng Yu, Lou Haizhou, Fang Yong, Jin Wei, Pan Hongming, Wang Kaifeng
Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Oncol Res. 2016;23(5):219-28. doi: 10.3727/096504016X14567549091260.
Radiofrequency ablation (RFA) is a minimally invasive technology for the treatment of liver malignancies and is used as an adjuvant therapy in patients with colorectal liver metastasis (CLM). This study enrolled a total of 49 CLM patients who underwent RFA treatment. Univariate and multivariate analyses were performed using the log-rank test and Cox proportional hazard model, respectively. Univariate analysis showed that OS was closely correlated with tumor size, frequency of RFA treatment, resection of the liver lesion, and CEA levels before RFA (p < 0.05). Multivariate analysis revealed that resection of CLM lesions after RFA, frequency of RFA treatment, and serum CEA levels before RFA were independent risk factors for the survival of CLM patients (p < 0.05). Tumor lesion size, resection of the liver lesion after RFA, frequency of RFA treatment, and serum CEA levels before RFA may be important prognostic factors of CLM patients treated with RFA therapy.
射频消融(RFA)是一种用于治疗肝脏恶性肿瘤的微创技术,在结直肠癌肝转移(CLM)患者中用作辅助治疗。本研究共纳入49例接受RFA治疗的CLM患者。分别使用对数秩检验和Cox比例风险模型进行单因素和多因素分析。单因素分析显示,总生存期(OS)与肿瘤大小、RFA治疗频率、肝病灶切除以及RFA术前癌胚抗原(CEA)水平密切相关(p < 0.05)。多因素分析表明,RFA术后CLM病灶切除、RFA治疗频率以及RFA术前血清CEA水平是CLM患者生存的独立危险因素(p < 0.05)。肿瘤病灶大小、RFA术后肝病灶切除、RFA治疗频率以及RFA术前血清CEA水平可能是接受RFA治疗的CLM患者重要的预后因素。